SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ICOS Corporation
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (1032)2/10/2004 9:50:17 PM
From: tom pope  Read Replies (1) of 1139
 
I was surprised to find that Viagra is not that important in the overall PFE line-up (revenues, not necessarily profits). This from my ML guy:(he said proposes when he meant purposes, not me.)

According to S&P, copy is in the mail for compliance proposes:
"We expect 2004 sales to climb 16%, exceeding $52 billion,
Viagra $1.9 billion
Lipator 9.2 billion
Norvasc 4.3 billion
Celebrex/Bestra 2.6 billion
Zyrtec 1.3 billion
Zoloft 3.1 billion
Neurontin 2.7 billion..."
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News